"10.1371_journal.pone.0108751","plos one","2014-10-10T00:00:00Z","Benjamin Heidrich; Steffen B Wiegand; Peter Buggisch; Holger Hinrichsen; Ralph Link; Bernd Möller; Klaus H W Böker; Gerlinde Teuber; Hartwig Klinker; Elmar Zehnter; Uwe Naumann; Heiner W Busch; Benjamin Maasoumy; Undine Baum; Svenja Hardtke; Michael P Manns; Heiner Wedemeyer; Jörg Petersen; Markus Cornberg; for the HepNet Study Group","Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; German Liver Foundation, HepNet Study-House, Hannover, Germany, and German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany; IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St Georg, Hamburg, Germany; Gastroenterology, Gastroenterologische Schwerpunkt Praxis, Kiel, Germany; St. Josefs hospital, Offenburg, Germany; Medical Practice, Berlin, Germany; Leberpraxis, Hannover, Germany; Gastroenterological Practice, Frankfurt, Germany; Dept. of Internal Medicine II, University of Würzburg, Würzburg, Germany; Gastroenterological Practice, Dortmund, Germany; Center for Addiction-Medicine, Hepatology and HIV, Praxiszentrum Kaiserdamm, Berlin, Germany; Medical Practice, Münster, Germany","Conceived and designed the experiments: MC HW MPM BH SBW. Performed the experiments: PB HH RL BM KHWB GT HK EZ UN HWB UB SH MPM HW JP MC BH SBW. Analyzed the data: BH SBW MC. Contributed reagents/materials/analysis tools: PB HH RL BM KHWB GT HK EZ UN HWB UB SH MPM HW JP MC BH SBW. Wrote the paper: BH SBW MC HW BM.","Markus Cornberg has read the journals policy and the authors of this manuscript have the following competing interests: Benjamin Heidrich: nothing to disclose; Steffen B. Wiegand: nothing to disclose; Peter Buggisch: Honoraria for consulting or speaking: Gilead, Roche, MSD, Janssen, BMS und AbbVie; Holger Hinrichsen: nothing to disclose; Ralph Link: nothing to disclose; Bernd Möller: nothing to disclose; Klaus H. W. Böker: Honoraria for speaking: Bristol-Myers-Squibb, Gilead, Roche Pharma, Merck (MSD Sharp & Dohme GmbH), Novartis; Janssen-Cilag, Gilead; Gerlinde Teuber: received financial support for advise and talk from: Roche, MSD, Bristol-Myers Squibb, Janssen-Cilag, Gilead, AbbVie; Hartwig Klinker: received grants, Board membership fees and lecture fees from: AbbVie, Boehringer, Bristol-Myers Squibb, Gilead, Glaxo-SmithKline, Hexal, Janssen-Cilag, MSD, Roche, and ViiV Healthcare; Elmar Zehnter: nothing to disclose; Uwe Naumann: received financial support for research, advise and talk from: Roche, MSD, Bristol-Myers Squibb, Janssen-Cilag, Gilead, ViiV, AbbVie, Boehringer Ingelheim; Heiner W. Busch: Honoraria for speaking: Gilead, Janssen-Cilag, MSD Sharp & Dohme, Roche, ViiV; Benjamin Maasoumy: Honoraria for consulting or speaking: Roche Pharma, Roche Diagnostics, Abbott Molecular, Merck, MSD Sharp & Dohme, Janssen/Janssen TE, Fujirebio; Undine Baum: nothing to disclose; Svenja Hardtke: nothing to disclose; Michael P. Manns: received financial compensation for consultancy and/or lecture activities from: Roche, Bristol Myers Squibb, Gilead, Boehringer Ingelheim, Novartis, Merck, Janssen, Idenix and GlaxoSmithKline, and research grants from: Roche, Gilead, Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Merck and Janssen; Heiner Wedemeyer: Honoraria for consulting or speaking: Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Gilead, ITS, JJ/Janssen-Cilag, Medgenics, Merck/Schering-Plough, Novartis, Roche, Roche Diagnostics, Siemens, Transgene, ViiV and research grants: Abbott, BMS, Gilead, Merck, Novartis, Roche Diagnostics, Siemens; Jörg Petersen: Grant/Research Support: BMS, Novartis, Roche and Consultant/Advisor: Abbott, AbbVie, BMS, Boehringer, Gilead, GSK, Kedrion, Janssen, Merck, MSD, Novartis, Roche and Sponsored lectures: Abbott, BMS, Boehringer, Gilead, Kedrion, Janssen, Merck, MSD, Novartis, Roche; Markus Cornberg: Lecture fees: Bristol-Myers-Squibb, Boehringer Ingelheim, Gilead, Roche Pharma, Roche Diagnostics, Merck (MSD Sharp & Dohme GmbH), Novartis, Falk and research support: Gilead, Roche Pharma, Roche Diagnostics, Merck (MSD Sharp & Dohme GmbH) and consultant fees: Abbvie, Boehringer Ingelheim, Gilead, Roche Pharma, Roche Diagnostics, Merck (MSD Sharp & Dohme GmbH), Novartis. This registry was financially supported by MSD Sharp & Dohme GmbH (manufacturer of pegylated interferon alpha-2b). The protocol and the contracts did not intend to influence the decision to treat patients with pegylated interferon alpha-2b. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","10","Benjamin Heidrich","BH",20,TRUE,5,18,3,5,TRUE,TRUE,TRUE,1,"20",TRUE
